Loading...

Instem

AIM:INS
Snowflake Description

Excellent balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
INS
AIM
£49M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Instem plc provides information technology solutions to the life science market worldwide. The last earnings update was 178 days ago. More info.


Add to Portfolio Compare Print
INS Share Price and Events
7 Day Returns
0%
AIM:INS
1.6%
GB Healthcare Services
1.9%
GB Market
1 Year Returns
62.9%
AIM:INS
23.6%
GB Healthcare Services
1.2%
GB Market
INS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Instem (INS) 0% -6.2% 32.9% 62.9% 46% 63.8%
GB Healthcare Services 1.6% 0.4% 13% 23.6% 39.4% 134%
GB Market 1.9% 1.5% 9.1% 1.2% 14.5% 3.1%
1 Year Return vs Industry and Market
  • INS outperformed the Healthcare Services industry which returned 23.6% over the past year.
  • INS outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned 1.2% over the past year.
Price Volatility
INS
Industry
5yr Volatility vs Market

INS Value

 Is Instem undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Instem to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Instem.

AIM:INS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year GB Government Bond Rate 1.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for AIM:INS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 1.2%
Equity Risk Premium S&P Global 6.7%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.22
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.222 (1 + (1- 19%) (0.07%))
1.149
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.15
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.23% + (1.149 * 6.65%)
8.87%

Discounted Cash Flow Calculation for AIM:INS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Instem is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

AIM:INS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 8.87%)
2019 3.60 Analyst x1 3.31
2020 2.90 Analyst x1 2.45
2021 2.47 Est @ -14.68% 1.92
2022 2.23 Est @ -9.91% 1.59
2023 2.08 Est @ -6.57% 1.36
2024 1.99 Est @ -4.23% 1.20
2025 1.94 Est @ -2.59% 1.07
2026 1.91 Est @ -1.45% 0.97
2027 1.90 Est @ -0.64% 0.89
2028 1.90 Est @ -0.08% 0.81
Present value of next 10 years cash flows £15.56
AIM:INS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £1.90 × (1 + 1.23%) ÷ (8.87% – 1.23%)
£25.18
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £25.18 ÷ (1 + 8.87%)10
£10.76
AIM:INS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £15.56 + £10.76
£26.32
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £26.32 / 16.25
£1.62
AIM:INS Discount to Share Price
Calculation Result
Value per share (GBP) From above. £1.62
Current discount Discount to share price of £3.03
= -1 x (£3.03 - £1.62) / £1.62
-87%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Instem is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Instem's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Instem's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:INS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in GBP £0.12
AIM:INS Share Price ** AIM (2019-03-21) in GBP £3.03
Europe Healthcare Services Industry PE Ratio Median Figure of 17 Publicly-Listed Healthcare Services Companies 29.19x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 808 Publicly-Listed Companies 15.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Instem.

AIM:INS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:INS Share Price ÷ EPS (both in GBP)

= 3.03 ÷ 0.12

26.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Instem is good value based on earnings compared to the Europe Healthcare Services industry average.
  • Instem is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Instem's expected growth come at a high price?
Raw Data
AIM:INS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 26.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Europe Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 576 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Instem, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Instem's assets?
Raw Data
AIM:INS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in GBP £1.00
AIM:INS Share Price * AIM (2019-03-21) in GBP £3.03
United Kingdom of Great Britain and Northern Ireland Healthcare Services Industry PB Ratio Median Figure of 8 Publicly-Listed Healthcare Services Companies 3.02x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,359 Publicly-Listed Companies 1.5x
AIM:INS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:INS Share Price ÷ Book Value per Share (both in GBP)

= 3.03 ÷ 1.00

3.03x

* Primary Listing of Instem.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Instem is overvalued based on assets compared to the GB Healthcare Services industry average.
X
Value checks
We assess Instem's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Instem has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

INS Future Performance

 How is Instem expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.7%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Instem expected to grow at an attractive rate?
  • Instem's earnings growth is expected to exceed the low risk savings rate of 1.2%.
Growth vs Market Checks
  • Instem's earnings growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.
  • Instem's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:INS Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:INS Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 10.7%
AIM:INS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 9.7%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 15.2%
United Kingdom of Great Britain and Northern Ireland Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 18.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 11.2%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:INS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:INS Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 28 5 2
2019-12-31 25 6 2
2018-12-31 23 3 2
AIM:INS Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-06-30 22 4 2
2018-03-31 22 3 1
2017-12-31 22 1 1
2017-09-30 21 1 1
2017-06-30 20 0 0
2017-03-31 19 0 1
2016-12-31 18 0 1
2016-09-30 18 1 0
2016-06-30 18 2 -1
2016-03-31 17 2 0
2015-12-31 16 3 0
2015-09-30 16 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Instem's earnings are expected to grow by 10.7% yearly, however this is not considered high growth (20% yearly).
  • Instem's revenue is expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:INS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Instem Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:INS Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 0.11 0.11 0.11 1.00
2019-12-31 0.09 0.09 0.09 1.00
2018-12-31 0.06 0.06 0.06 1.00
AIM:INS Past Financials Data
Date (Data in GBP Millions) EPS *
2018-06-30 0.12
2018-03-31 0.09
2017-12-31 0.07
2017-09-30 0.04
2017-06-30 0.02
2017-03-31 0.04
2016-12-31 0.07
2016-09-30 0.02
2016-06-30 -0.04
2016-03-31 -0.04
2015-12-31 -0.03
2015-09-30 0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Instem is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Instem's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Instem has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

INS Past Performance

  How has Instem performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Instem's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Instem has delivered over 20% year on year earnings growth in the past 5 years.
  • Instem's 1-year earnings growth exceeds its 5-year average (517.5% vs 21%)
  • Instem's earnings growth has exceeded the Europe Healthcare Services industry average in the past year (517.5% vs 11.5%).
Earnings and Revenue History
Instem's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Instem Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:INS Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 21.87 1.83 1.03
2018-03-31 21.77 1.46 0.95
2017-12-31 21.67 1.09 0.87
2017-09-30 20.61 0.70 0.82
2017-06-30 19.55 0.30 0.77
2017-03-31 18.93 0.68 0.83
2016-12-31 18.32 1.06 0.88
2016-09-30 18.11 0.25 0.86
2016-06-30 17.89 -0.57 0.84
2016-03-31 17.11 -0.50 0.81
2015-12-31 16.32 -0.43 0.77
2015-09-30 15.76 0.24 0.70
2015-06-30 15.21 0.92 0.63
2015-03-31 14.32 0.53 0.57
2014-12-31 13.43 0.15 0.52
2014-09-30 12.50 0.10 0.56
2014-06-30 11.58 0.04 0.60
2014-03-31 11.47 0.28 0.61
2013-12-31 11.36 0.53 0.61
2013-09-30 11.32 0.76 0.60
2013-06-30 11.28 0.98 0.59
2013-03-31 10.97 1.01 0.59
2012-12-31 10.66 1.04 0.59
2012-09-30 10.72 0.96 0.58
2012-06-30 10.77 0.87 0.57
2012-03-31 10.78 0.94 0.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Instem has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Instem used its assets less efficiently than the Europe Healthcare Services industry average last year based on Return on Assets.
  • Instem's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Instem's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Instem has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

INS Health

 How is Instem's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Instem's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Instem is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Instem's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Instem's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 346x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Instem Company Filings, last reported 8 months ago.

AIM:INS Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 15.91 0.04 3.74
2018-03-31 15.91 0.04 3.74
2017-12-31 14.23 0.08 3.06
2017-09-30 14.23 0.08 3.06
2017-06-30 12.11 0.00 1.17
2017-03-31 12.11 0.00 1.17
2016-12-31 12.78 0.11 4.19
2016-09-30 12.78 0.11 4.19
2016-06-30 11.49 0.00 4.76
2016-03-31 11.49 0.00 4.76
2015-12-31 6.61 0.15 2.18
2015-09-30 6.61 0.15 2.18
2015-06-30 5.40 1.69 1.60
2015-03-31 5.40 1.69 1.60
2014-12-31 5.42 0.30 1.68
2014-09-30 5.42 0.30 1.68
2014-06-30 4.51 0.19
2014-03-31 4.51 0.19
2013-12-31 4.97 0.00 2.05
2013-09-30 4.97 0.00 2.05
2013-06-30 4.85 0.00 0.93
2013-03-31 4.85 0.00 0.93
2012-12-31 5.00 0.25 2.45
2012-09-30 5.00 0.25 2.45
2012-06-30 4.07 0.25 1.85
2012-03-31 4.07 0.25 1.85
  • Instem's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.2% today).
  • Debt is well covered by operating cash flow (12608.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 21.6x coverage).
X
Financial health checks
We assess Instem's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Instem has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

INS Dividends

 What is Instem's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Instem dividends. Estimated to be 0% next year.
If you bought £2,000 of Instem shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Instem's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Instem's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:INS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 704 Stocks 4.3%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:INS Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Instem has not reported any payouts.
  • Unable to verify if Instem's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Instem's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Instem has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Instem's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Instem's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Instem afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Instem has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

INS Management

 What is the CEO of Instem's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Phil Reason
COMPENSATION £246,000
AGE 56
CEO Bio

Mr. Phil J. Reason serves as the Chief Executive Officer of Instem LSS Limited, Instem Associates Limited and Instem plc (Instem Life Science Systems plc). Mr. Reason is an experienced chief executive who has developed a number of IT businesses in the life sciences and nuclear industries, both organically and through acquisition. He joined the former parent Company, Instem Limited, in 1982 and was appointed Managing Director of the Life Sciences division in 1995 and Chief Executive Officer of Instem LSS Limited on the demerger from Instem Limited. He serves as an Executive Director of Instem plc.

CEO Compensation
  • Phil's compensation has been consistent with company performance over the past year.
  • Phil's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure of the Instem management team in years:

2.6
Average Tenure
  • The tenure for the Instem management team is about average.
Management Team

Phil Reason

TITLE
CEO & Executive Director
COMPENSATION
£246K
AGE
56

Nigel Goldsmith

TITLE
CFO, Secretary & Executive Director
COMPENSATION
£134K
AGE
56
TENURE
7.3 yrs

Marybeth Thompson

TITLE
Chief Operating Officer
TENURE
2.2 yrs

Gordon Baxter

TITLE
Chief Scientific Officer

Gary Mitchell

TITLE
Vice President of Global Marketing

Jerry Hacker

TITLE
Senior Vice President of Global Sales
TENURE
2.6 yrs

Adrian Gare

TITLE
Vice President of Corporate Development

Mike Harwood

TITLE
Executive Vice President of Regulatory eStudy Solutions

Gregor Grant

TITLE
Executive Vice President of Preclinical Solutions

Steve Gooderham

TITLE
Vice President of Global Operations
Board of Directors

David Gare

TITLE
Non-Executive Chairman
COMPENSATION
£60K
AGE
74

Phil Reason

TITLE
CEO & Executive Director
COMPENSATION
£246K
AGE
56

Nigel Goldsmith

TITLE
CFO, Secretary & Executive Director
COMPENSATION
£134K
AGE
56
TENURE
7.3 yrs

Mike McGoun

TITLE
Independent Non-Executive Director
COMPENSATION
£30K
AGE
71

David Sherwin

TITLE
Non-Executive Director
COMPENSATION
£30K
AGE
61
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
X
Management checks
We assess Instem's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Instem has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

INS News

Simply Wall St News

Is Instem plc's (LON:INS) CEO Pay Fair?

How Does Phil Reason's Compensation Compare With Similar Sized Companies. … According to our data, Instem plc has a market capitalization of UK£50m, and pays its CEO total annual compensation worth UK£246k. … While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at UK£210k

Simply Wall St -

Instem Shareholders Have Enjoyed A 86% Share Price Gain

For example, the Instem plc (LON:INS) share price is up 86% in the last 5 years, clearly besting than the market return of around 28%. … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … Over half a decade, Instem managed to grow its earnings per share at 5.4% a year.

Simply Wall St -

At UK£2.80, Is Instem plc (LON:INS) Worth Looking At Closely?

saw a significant share price rise of over 20% in the past couple of months on the AIM. … Less-covered, small caps tend to present more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing? … So, could the stock still be trading at a low price relative to its actual value.

Simply Wall St -

Taking A Look At Instem plc's (LON:INS) ROE

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every £1 worth of equity in the company, it was able to earn £0.12. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Does Instem plc (LON:INS)'s Capital Return Make The Cut?

and looking to gauge the potential return on investment in Instem plc (LON:INS). … Your equity share is granted in return for the capital provided to the business to operate, and in order for an investment to be successful the business has to create earnings from the funds that make up this capital. … Therefore, looking at how efficiently Instem is able to use capital to create earnings will help us understand your potential return.

Simply Wall St -

Calculating The Fair Value Of Instem plc (LON:INS)

How far off is Instem plc (LON:INS) from its intrinsic value? … by estimating the company's future cash flows and discounting them to their present value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

Does Instem plc's (LON:INS) PE Ratio Warrant A Sell?

Instem plc (LON:INS) is trading with a trailing P/E of 42.3, which is close to the industry average of 40.7. … While this might not seem positive, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions. … I will explain what the P/E ratio is as well as what you should look out for when using it

Simply Wall St -

What Should You Know About Instem plc's (LON:INS) Capital Returns?

This share represents a portion of capital used by the company to operate the business, and it is important the company is able to use the capital base efficiently to create adequate cash flows for you as an investor. … To understand Instem’s capital returns we will look at a useful metric called return on capital employed. … This will tell us if the company is growing your capital and placing you in good stead to sell your shares at a profit

Simply Wall St -

Calculating The Intrinsic Value Of Instem plc (LON:INS)

by estimating the company's future cash flows and discounting them to their present value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Should You Buy Instem plc (LON:INS)?

Today I will analyse the most recent data on Instem’s outlook and valuation to see if the opportunity still exists? … The stock seems fairly valued at the moment according to my valuation model … 5.14% above my intrinsic value, which means if you buy Instem today, you’d be paying a relatively

Simply Wall St -

INS Company Info

Description

Instem plc provides information technology solutions to the life science market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include Provantis, an integrated Windows-based system for organizations and universities that are engaged in non-clinical evaluation studies; submit platform that provides a suite of integrated tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; ALPHADAS, an eSource EDC system for early phase clinical trials; Animal Care Information System, an animal management software solution; Logbook, a repository for information; and Toxicology Resource Planning, a toxicology solution for pharmaceutical, chemical, and contract research laboratory corporations. The company also provides Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Sorcerer Colony Counter for automatic plate counter; Cyto Study Manager, a data acquisition and reporting solution; Ames Study Manager, plate countiner; Sorcerer Colony Counter for automatic plate counter; NOTOCORD-hem and NOTOCORD-fps software platforms to acquire, display, and analyze physiological signals; SEND Explorer, a Web-based application with optional data warehousing capabilities; and SRS data integration platform. It also provides data management, cloud, safety assessment, regulatory information management, solution deployment, and validation services. Additionally, it provides software solutions for extracting intelligence from research and development related healthcare data; and develops, manufactures, and supplies software and hardware products for in vitro study data collection and study management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.

Details
Name: Instem plc
INS
Exchange: AIM
Founded: 1969
£49,228,358
16,246,983
Website: http://www.instem.com
Address: Instem plc
Diamond Way,
Stone Business Park,
Stone,
Staffordshire, ST15 0SD,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM INS Ordinary Shares London Stock Exchange AIM Market GB GBP 13. Oct 2010
OTCPK IIIS.F Ordinary Shares Pink Sheets LLC US USD 13. Oct 2010
BST 54I Ordinary Shares Boerse-Stuttgart DE EUR 13. Oct 2010
Number of employees
Current staff
Staff numbers
217
Instem employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/21 21:58
End of day share price update: 2019/03/21 00:00
Last estimates confirmation: 2019/01/23
Last earnings filing: 2018/09/24
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.